Anales de la RANM

30 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 LINFOHISTICIOTOSIS HEMAFAGOCITICA DEL ADULTO José María Fernández-Rañada y de la Gándara An RANM. 2021;138(01): 24 - 30 7. Trottestam H, Horne A, Aricó M, et al. Che- moimmunotherapy for hemophagocytic lym- phohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011; 118(17): 4577-4584. 8. Ehl S, Astigarraga I, von Bahr Greenwood T, et al. Recommendations for the use of etoposide- based therapy and bone marrow transplanta- tion for the treatment of HLH: consensus sta- tements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Inmun. 2018; 6(5): 1508-1517. 9. Bergsten E, Horne A, Aricó Micó, et al. Con- firmed efficacy of etoposide and dexameta- sone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017; 130(25): 2728-2738. 10. Marsh RA. Epstein-Barr virus and hemophago- cytic Lymphohistiocyto. Front Immunol. 2018. https://doi.org/10.3389/fimmu.2017.01902 11. Horne AC, Wickström R, Jordan MB, et al. How to treat involvement of the central ner- vous system in hemophagocytic lymphohistio- cytosis? Curr Treat Options Neurol. 2017; 19: e3. 12. Hayden A, Park S, Giustini D, Lee AYY, Chen LYC. Hemophagocytic syndromes (HPSs) in- cluding hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Rev. 2016; 30(6): 411-420. 13. Hayden A, Lin M, Park S, et al. Soluble inter- leukin-2 receptor is a sensitive diagnostic test in adult HLH. Blood adv. 2017; 1(26): 2529- 2534. 14. Marsh RA, Haddad E. How I treat primary haemophagocytic lymphohistiocytosis. Br J Haematol. 2018; 182(2): 185-199. 15. Wang Y, Wang Z. Treatment of hemophago- cytic lymphohistiocytosis. Curr Opin Hema- tol. 2017; 24(1): 54-58. 16. Daver N, McClain K, Allen CE, et al. A con- sensus review on malignancy-associated he- mophagocytic lymphohistiocytosis in adults. Cancer. 2017; 123: 3229-3240. 17. La Rosée P, Horne AC, Hines M, et al. Recom- mendations for the management of hemopha- gocytic lymphohistocytosis in adults. Blood. 2019; 133(23): 2465-2477. 18. Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed/refractory hemopha- gocytic lymphohistiocytosis. Blood. 2019; 134(21): 1783-1786. 19. Ahmed A, Merrill SA, Alsawah F, et al. Ruxo- litinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019; 6(12): e630-e637. DECLARACIÓN DE TRANSPARENCIA El autor/a de este artículo declara no tener ningún tipo de conflicto de intereses respecto a lo expuesto en el presente trabajo. Si desea citar nuestro artículo: Fernández-Rañada y de la Gándara JM. Linfohisticiotosis hema- fagocitica del adulto (LHH). Síndrome y enfermedad. An RANM. 2021;138(01): 24– 30. DOI: 10.32440/ar.2021.138.01. rev03